StemSight, headquartered in Helsinki, Finland, is pioneering regenerative medicine to restore sight using advanced stem cell technologies. The company focuses on developing corneal cell therapies for patients suffering from blindness due to limbal stem cell deficiency—an often untreatable condition.
By creating bioengineered tissues and using patient-compatible stem cells, StemSight offers a potential cure that avoids traditional corneal transplant limitations, such as donor scarcity and rejection. Their process involves producing off-the-shelf, ready-to-implant cell therapies that are scalable, safe, and effective. StemSight’s innovation stands at the intersection of biotechnology, ophthalmology, and tissue engineering, offering new hope to millions of people with corneal diseases.
Beyond corneal repair, the platform holds promise for other regenerative applications. The company’s mission is to make regenerative eye care accessible and reliable, setting a new benchmark for vision restoration through science.
